Rouamba: Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso [HCQ]

Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso

Rouamba et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.034, NCT04445441 (history)

Rouamba et al., Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.034, NCT04445441

Feb 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 863 COVID-19 patients in Burkina Faso, showing lower mortality, lower progression for outpatients, and faster viral clearance with HCQ/CQ treatment. Only the lower mortality was statistically significant. NCT04445441 (history).

Important missing comments or errors? Let us know.

risk of death, 80.0% lower, HR 0.20, p < 0.001, treatment 20 of 336 (6.0%), control 24 of 73 (32.9%), NNT 3.7, adjusted per study, inpatients, multivariable, Cox proportional hazards.

risk of progression, 20.0% lower, HR 0.80, p = 0.43, treatment 75 of 745 (10.1%), control 19 of 118 (16.1%), adjusted per study, all patients, multivariable, Cox proportional hazards.

risk of progression, 73.0% lower, HR 0.27, p = 0.05, treatment 23 of 399 (5.8%), control 4 of 33 (12.1%), adjusted per study, outpatients, multivariable, Cox proportional hazards, early treatment result.

risk of progression, 7.0% higher, HR 1.07, p = 0.83, treatment 52 of 347 (15.0%), control 15 of 85 (17.6%), adjusted per study, inpatients, multivariable, Cox proportional hazards.

time to viral clearance, 30.6% lower, HR 0.69, p = 0.26, treatment 746, control 118, adjusted per study, inverted to make HR<1 favor treatment, all patients, propensity score matching, multivariable, Cox proportional hazards, primary outcome.

time to viral clearance, 13.0% lower, HR 0.87, p = 0.29, treatment 746, control 118, adjusted per study, inverted to make HR<1 favor treatment, all patients, without PSM, multivariable, Cox proportional hazards, primary outcome.

time to viral clearance, 21.3% lower, HR 0.79, p = 0.37, treatment 399, control 33, adjusted per study, inverted to make HR<1 favor treatment, outpatients, multivariable, Cox proportional hazards, primary outcome, early treatment result.

time to viral clearance, 13.8% lower, HR 0.86, p = 0.37, treatment 345, control 86, adjusted per study, inverted to make HR<1 favor treatment, inpatients, multivariable, Cox proportional hazards, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Rouamba et al., 26 Feb 2022, retrospective, Burkina Faso, peer-reviewed, mean age 42.2, 17 authors, study period 9 March, 2020 - 31 October, 2020, dosage 200mg tid days 1-10, HCQ 200mg tid daily or CQ 250mg bid daily, trial NCT04445441 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: Journal Pre-proof Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso Toussaint Rouamba , Esperance Ouédraogo , Houreratou Barry , Nobila Valentin Yaméogo , Apoline Sondo , Rainatou Boly , Jacques Zoungrana , Abdoul Risgou Ouédraogo , Marc Christian Tahita , Armel Poda , Arnaud Eric Diendéré , Abdoul-Salam Ouedraogo , Innocent Valea , Isidore Traoré , Zekiba Tarnagda , Maxime K. Drabo , Halidou Tinto , on behalf of the CHLORAZ study group PII: DOI: Reference: S1201-9712(22)00111-4 https://doi.org/10.1016/j.ijid.2022.02.034 IJID 6025 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 29 December 2021 13 February 2022 15 February 2022 Please cite this article as: Toussaint Rouamba , Esperance Ouédraogo , Houreratou Barry , Nobila Valentin Yaméogo , Apoline Sondo , Rainatou Boly , Jacques Zoungrana , Abdoul Risgou Ouédraogo , Marc Christian Tahita , Armel Poda , Arnaud Eric Diendéré , Abdoul-Salam Ouedraogo , Innocent Valea , Isidore Traoré , Zekiba Tarnagda , Maxime K. Drabo , Halidou Tinto , on behalf of the CHLORAZ study group, Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.02.034 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Highlights  Hydroxychloroquine+azithromycin (HCQ+AZ) did not reduce recovery time in COVID19  HCQ+AZ had no effect on the risk of worsening or transfer to the intensive care  The use of HCQ+AZ appeared to be associated with lower mortality rates 1 Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso Toussaint Rouambaa*ǂ, Esperance Ouédraogoaǂ, Houreratou Barryb, Nobila Valentin Yaméogoc, Apoline Sondoc, Rainatou Bolyd, Jacques Zoungranad, Abdoul Risgou Ouédraogoe, Marc Christian Tahitaa, Armel Podad, Arnaud Eric Diendéréf, Abdoul-Salam Ouedraogod, Innocent Valeaa, Isidore Traoréb, Zekiba Tarnagdaa, Maxime K Draboa and Halidou Tintoa on behalf of the CHLORAZ study group. a Institut de Recherche en Sciences de la Santé, CNRST (IRSS- CNRST), Burkina Faso ; b Institut National de Santé Publique – Centre Muraz, Bobo-Dioulasso, Burkina Faso ; c Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso ; d Centre Hospitalier Universitaire Sourou Sanon, Bobo-Dioulasso, Burkina..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit